| 000 | 01417 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517212217.0 | ||
| 264 | 0 | _c20190128 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1475-2840 | ||
| 024 | 7 |
_a10.1186/s12933-018-0704-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAroor, Annayya R | |
| 245 | 0 | 0 |
_aThe role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. _h[electronic resource] |
| 260 |
_bCardiovascular diabetology _c04 2018 |
||
| 300 |
_a59 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdrug therapy |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xdrug therapy |
| 650 | 0 | 4 |
_aDipeptidyl Peptidase 4 _xmetabolism |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLinagliptin _xadverse effects |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aManrique-Acevedo, Camila | |
| 700 | 1 | _aDeMarco, Vincent G | |
| 773 | 0 |
_tCardiovascular diabetology _gvol. 17 _gno. 1 _gp. 59 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12933-018-0704-1 _zAvailable from publisher's website |
| 999 |
_c28301258 _d28301258 |
||